[Leukaemic phase of Mantle zone (intermediate) lymphoma--case report--]

Insights

The leukaemic phase of Mantle zone lymphoma involves lymphoma cells in the blood and bone marrow. This case report highlights a patient with this rare condition, showing a poor prognosis despite treatment.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Leukaemic phase of non-Hodgkin lymphoma (NHL) involves lymphoma cell infiltration into peripheral blood and bone marrow.
  • Mantle zone lymphoma (MZL) is an intermediate lymphoma subtype.
  • Diagnosis relies on histology, peripheral blood smear, and immunophenotype.

Observation:

  • A 60-year-old patient presented with leukaemic phase Mantle zone lymphoma.
  • Clinical signs included pallor, lymphadenopathy, and hepatomegaly.
  • Peripheral blood showed elevated WBC count (22.5 x 10^9/L) with pleomorphic lymphoid cells.

Findings:

  • Immunophenotype confirmed Mantle zone lymphoma: Smlg+ (lambda), HLA-DR+, CD19+, CD22+, CD5+, CD10-, CD25-.
  • Treatment with Pro-MACE-Cyta-bom protocol achieved a 13-month remission.
  • Overall survival was 20 months.

Implications:

  • The leukaemic phase of Mantle zone lymphoma indicates a poor prognosis.
  • This case underscores the importance of comprehensive diagnostic methods.
  • Further research into prognostic factors and treatment strategies is warranted.